ea0005p181 | Neuroendocrinology and Behaviour | BES2003
Mah P
, Walters S
, Newell-Price J
, Webster J
, Doane A
, Ibbotson V
, Hosker J
, Jones T
, Ho K
, Eastell R
, Ross R
AIM: To assess efficacy of GH replacement and safety of stopping treatment in patients aged over 60 years.METHODS: GH-deficient patients were started on GH 0.13 miligram per day and the dose titrated over 4 months to a serum IGF-1 in the upper half of the age-related normal range. After 4 months titration, patients were randomised to either continuing GH or placebo in a double-blind, cross-over study with 2 x 4 month periods of either GH or placebo treatment.RESULTS: 1...